Mycophenolate Mofetil Teva: Uses, Dosage & Side Effects

What Is Mycophenolate Mofetil Teva and What Is It Used For?

Mycophenolate Mofetil Teva contains the active substance mycophenolate mofetil, a potent immunosuppressive agent that belongs to the pharmacological class of selective immunosuppressants (ATC code L04AA06). Mycophenolate mofetil is the 2-morpholinoethyl ester of mycophenolic acid (MPA), a natural fermentation product of several Penicillium species. After oral administration, mycophenolate mofetil acts as a prodrug that is rapidly and completely hydrolysed to its active metabolite, mycophenolic acid. MPA was first identified for its immunosuppressive properties in the 1990s, and mycophenolate mofetil has since become one of the cornerstones of modern transplant immunosuppressive therapy worldwide.

The mechanism of action of MPA is highly selective and well-characterized. MPA is a potent, selective, non-competitive, and reversible inhibitor of inosine 5′-monophosphate dehydrogenase (IMPDH), specifically the type II isoform that is preferentially expressed in activated lymphocytes. IMPDH is a rate-limiting enzyme in the de novo biosynthetic pathway of guanosine nucleotides. Unlike most other cell types in the body, T and B lymphocytes are critically dependent on this de novo pathway for their proliferation. Other cell types can utilise alternative salvage pathways to synthesize purines, making them less susceptible to IMPDH inhibition. This selectivity gives mycophenolate mofetil a more targeted immunosuppressive profile compared to older agents such as azathioprine, which affects purine synthesis in a non-selective manner.

By inhibiting IMPDH and depleting the intracellular pool of guanosine nucleotides in lymphocytes, MPA exerts multiple immunosuppressive effects. It suppresses the proliferation of both T lymphocytes and B lymphocytes in response to mitogenic and allospecific stimulation. It inhibits antibody formation by B lymphocytes, thereby reducing the humoral immune response against the transplanted organ. MPA also decreases the recruitment of inflammatory cells to sites of graft rejection by inhibiting the glycosylation and expression of adhesion molecules on lymphocytes, which reduces their ability to bind to vascular endothelium in the transplanted organ.

Mycophenolate Mofetil Teva is indicated for the prophylaxis of acute transplant rejection in patients receiving allogeneic organ transplants. Specifically, it is approved for use in combination with ciclosporin and corticosteroids for the prevention of acute rejection in the following transplant settings:

• Kidney transplantation: This is the most common and most extensively studied indication. In the landmark pivotal trials (the Tricontinental Mycophenolate Mofetil Renal Transplantation Study, the European Mycophenolate Mofetil Cooperative Study, and the US Renal Transplant Mycophenolate Mofetil Study), mycophenolate mofetil 2 g/day significantly reduced the incidence of treatment failure (biopsy-proven acute rejection, graft loss, death, or early termination) compared to azathioprine or placebo. Biopsy-proven acute rejection rates at 6 months were approximately 17–20% with mycophenolate mofetil versus 35–46% with comparators.
• Heart transplantation: Mycophenolate mofetil has been shown to reduce mortality at 12 months and decrease the incidence of rejection requiring treatment in heart transplant recipients when compared to azathioprine-based regimens.
• Liver transplantation: In liver transplant recipients, mycophenolate mofetil in combination with ciclosporin and corticosteroids demonstrated comparable efficacy to azathioprine-based regimens in preventing acute rejection, with a favorable overall safety profile.

Today, mycophenolate mofetil is recommended by major international guidelines as a first-line antiproliferative agent in maintenance immunosuppressive regimens following solid organ transplantation. The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend mycophenolate-based therapy as the preferred initial antiproliferative agent for kidney transplant recipients. Similarly, the International Society for Heart and Lung Transplantation (ISHLT) guidelines support the use of mycophenolate mofetil as the preferred antimetabolite in heart transplantation. Its widespread adoption reflects over two decades of clinical experience and robust evidence from randomized controlled trials demonstrating superior efficacy over azathioprine in preventing acute rejection episodes.

What Should You Know Before Taking Mycophenolate Mofetil Teva?

Mycophenolate Mofetil Teva is a powerful immunosuppressive medication that carries significant risks alongside its therapeutic benefits. Before starting treatment, several important factors must be carefully evaluated by your transplant physician. Understanding these considerations is essential for safe and effective use of this medication. Only physicians experienced in immunosuppressive therapy and the management of organ transplant recipients should prescribe mycophenolate mofetil.

Contraindications

Mycophenolate mofetil must not be used in certain situations due to unacceptable risks. The following are absolute contraindications to treatment:

• Hypersensitivity: Do not take mycophenolate mofetil if you are allergic to mycophenolate mofetil, mycophenolic acid, or any of the excipients. Hypersensitivity reactions including anaphylaxis have been reported.
• Pregnancy: Mycophenolate mofetil is teratogenic and must not be initiated in women of childbearing potential without confirmation of a negative pregnancy test. Treatment must not be started until a negative pregnancy test result has been obtained.
• Women of childbearing potential not using effective contraception: Women of childbearing potential must use at least one reliable form of contraception (preferably two complementary methods) before beginning treatment, during treatment, and for 6 weeks after discontinuation.
• Breastfeeding: Mycophenolate mofetil is contraindicated during breastfeeding because MPA is excreted in breast milk and may cause serious adverse effects in the nursing infant.

Warnings and Precautions

Immunosuppressive therapy with mycophenolate mofetil increases the overall risk of infections and malignancies. Patients should be informed of these risks and monitored carefully throughout treatment. The following warnings are particularly important:

• Infections: Patients receiving immunosuppressive regimens involving combinations of drugs, including mycophenolate mofetil, are at increased risk of opportunistic infections (bacterial, fungal, viral, and protozoal), including cytomegalovirus (CMV) viremia and disease, herpes simplex, herpes zoster, BK virus-associated nephropathy, and JC virus-associated progressive multifocal leukoencephalopathy (PML). Fatal infections and sepsis have been reported. Patients should be advised to report any signs of infection immediately.
• Malignancies: As with other immunosuppressive agents, there is an increased risk of lymphoproliferative disorders (including post-transplant lymphoproliferative disorder, PTLD) and other malignancies, particularly skin cancers. The risk appears to be related to the intensity and duration of immunosuppression rather than to any specific agent. Patients should minimize exposure to sunlight and ultraviolet light by wearing protective clothing and using high-factor sunscreen.
• Blood disorders: Mycophenolate mofetil can cause severe cytopenias including neutropenia, leukopenia, anaemia, thrombocytopenia, and pancytopenia. Patients should be monitored with complete blood counts weekly during the first month of treatment, twice monthly during months 2 and 3, and monthly thereafter through the first year. If clinically significant cytopenias develop, dose reduction or interruption may be necessary.
• Gastrointestinal disorders: Gastrointestinal tract complications including ulceration, haemorrhage, and perforation have been reported. Mycophenolate mofetil should be used with caution in patients with active serious digestive system disease.
• Pure red cell aplasia (PRCA): Cases of PRCA have been reported in patients treated with mycophenolate mofetil in combination with other immunosuppressive agents. Dose reduction or discontinuation may be required.

Pregnancy and Breastfeeding

Mycophenolate mofetil must not be used during pregnancy unless there is no suitable alternative treatment to prevent transplant rejection. If a woman becomes pregnant while taking mycophenolate mofetil, the drug should not be stopped without consulting the transplant physician, as abrupt discontinuation could put the transplanted organ at risk. The patient should be immediately referred to a physician specializing in teratology for assessment and counselling. Pregnancy prevention programmes must be implemented by the prescribing physician for all female patients of childbearing potential.

Male patients should also be counselled about reproductive risks. Although the risk from paternal exposure appears to be low based on available evidence, the current recommendation is that sexually active male patients or their female partners should use effective contraception during treatment and for at least 90 days after cessation of mycophenolate mofetil. Male patients should not donate semen during treatment and for 90 days following discontinuation.

Mycophenolate mofetil is excreted in breast milk in animal studies. It is not known whether MPA is excreted in human breast milk, but given the potential for serious adverse reactions in the nursing infant, breastfeeding is contraindicated during treatment with mycophenolate mofetil.

How Does Mycophenolate Mofetil Teva Interact with Other Drugs?

Drug interactions with mycophenolate mofetil are clinically significant because changes in MPA exposure can directly affect immunosuppressive efficacy and the risk of transplant rejection or drug toxicity. The enterohepatic recirculation of MPA (via its glucuronide metabolite MPAG) is an important pharmacokinetic feature that makes this drug susceptible to interactions with agents that alter gut flora, biliary excretion, or gastrointestinal absorption. Below are the most important drug interactions documented for mycophenolate mofetil.

Major Interactions

Minor Interactions

It is important to note that the pharmacokinetic interaction between mycophenolate mofetil and ciclosporin has significant clinical implications when switching between calcineurin inhibitors. When a patient is converted from ciclosporin to tacrolimus, or vice versa, MPA exposure may change substantially. Ciclosporin inhibits the biliary excretion of MPAG, reducing the enterohepatic recirculation of MPA and thereby lowering MPA plasma levels. Tacrolimus does not have this effect. Therefore, when patients are switched from ciclosporin to tacrolimus, MPA levels may increase by 30–50%, potentially requiring a reduction in the mycophenolate mofetil dose. Conversely, switching from tacrolimus to ciclosporin may necessitate a dose increase.

Patients should always inform their transplant team about any new medications, including over-the-counter drugs, herbal supplements, and dietary changes. Some herbal products, particularly St John’s wort (Hypericum perforatum), are known inducers of drug-metabolizing enzymes and transporters, and may potentially reduce MPA levels, although specific interaction studies are limited.

What Is the Correct Dosage of Mycophenolate Mofetil Teva?

Mycophenolate mofetil dosing varies according to the type of organ transplanted and patient characteristics. Treatment should be initiated by a transplant physician as early as possible after transplant surgery, typically within 72 hours. The tablets should be swallowed whole with a glass of water and can be taken with or without food, although consistent timing relative to meals is recommended for stable drug absorption. Do not crush, break, or chew the tablets, as this may alter the pharmacokinetic profile and increase gastrointestinal side effects.

Adults

Children

In paediatric kidney transplant recipients aged 2 years and older, the recommended dose is 600 mg/m² body surface area (BSA) administered orally twice daily, up to a maximum of 2 g daily (1 g twice daily). As the 500 mg film-coated tablet cannot be accurately divided, this formulation is most suitable for children with a BSA of 1.25 m² or greater. For smaller children, an oral suspension formulation may be more appropriate for accurate dosing. Mycophenolate mofetil is not approved for paediatric heart or liver transplant recipients due to insufficient clinical data in these populations.

Elderly

No specific dose adjustments are recommended for elderly patients. However, elderly transplant recipients may be at increased risk for adverse events, particularly infections and gastrointestinal complications, due to age-related changes in immune function, organ function, and overall physiological reserve. Close monitoring is recommended, and dose reductions may be necessary based on clinical response and tolerability. The pharmacokinetics of MPA in elderly patients have not been formally studied, but given the high prevalence of renal impairment in this population, MPA exposure may be altered.

Missed Dose

If you miss a dose of Mycophenolate Mofetil Teva, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. Maintaining consistent blood levels of the active metabolite MPA is important for preventing rejection episodes, so patients should be encouraged to set reminders and establish a regular medication routine. If multiple doses are missed, contact your transplant team promptly, as interruption of immunosuppressive therapy may increase the risk of acute rejection.

Overdose

Reports of overdose with mycophenolate mofetil have been received from clinical trials and post-marketing experience. In many of these cases, no adverse events were reported. Overdose events where adverse reactions were reported fall within the known safety profile of the drug – primarily haematological abnormalities (leukopenia, neutropenia) and gastrointestinal symptoms (diarrhoea, nausea, vomiting, abdominal pain). In the event of an overdose, general supportive measures should be employed. MPA is not efficiently removed by haemodialysis. However, at high plasma MPAG concentrations (greater than 100 µg/mL), small amounts of MPAG may be removed. Bile acid sequestrants such as cholestyramine may be administered to increase MPA elimination by interrupting enterohepatic recirculation. If overdose is suspected, seek immediate medical attention.

What Are the Side Effects of Mycophenolate Mofetil Teva?

Mycophenolate mofetil, like all immunosuppressive medications, carries a broad spectrum of potential adverse effects. The side effect profile is well characterized from extensive clinical trial data and decades of post-marketing surveillance. It is important to understand that many of the adverse effects observed in transplant recipients may be attributable to the combined immunosuppressive regimen (which typically includes a calcineurin inhibitor and corticosteroids) rather than mycophenolate mofetil alone. Nevertheless, certain adverse effects – particularly gastrointestinal disorders and specific haematological abnormalities – are clearly associated with mycophenolate mofetil.

The following classification of side effects is based on data from clinical trials and post-marketing surveillance. The frequency categories are defined as: Very common (≥1/10), Common (≥1/100 to <1/10), Uncommon (≥1/1,000 to <1/100), and Rare (<1/1,000).

The gastrointestinal adverse effects of mycophenolate mofetil are among the most clinically significant, as they frequently lead to dose reductions or medication changes. Diarrhoea is the most common side effect, affecting approximately 30–40% of patients, and can range from mild and self-limiting to severe and debilitating. The mechanism involves direct effects of MPA on rapidly dividing enterocytes in the gastrointestinal tract. In some cases, severe diarrhoea may necessitate dose reduction or conversion to enteric-coated mycophenolate sodium, which may offer improved gastrointestinal tolerability in some patients, although evidence for this is mixed.

Haematological adverse effects, particularly leukopenia and neutropenia, are common and can be dose-limiting. Leukopenia occurs in more than 10% of patients, and severe neutropenia (absolute neutrophil count less than 1.3 × 10³/µL) occurs in approximately 2–5% of patients. This increases the risk of serious and potentially life-threatening infections. Regular complete blood count monitoring is essential: weekly during the first month, twice monthly during months 2–3, and monthly thereafter through the first year. If neutropenia develops, dose reduction or temporary interruption of mycophenolate mofetil may be necessary, potentially alongside administration of granulocyte colony-stimulating factor (G-CSF).

The increased risk of infections is inherent to all immunosuppressive therapy, but certain infections are particularly associated with mycophenolate mofetil–containing regimens. CMV disease is a major concern, particularly in the first 3–6 months post-transplant. Prophylactic antiviral therapy (typically with valganciclovir) is standard practice in high-risk patients. BK virus nephropathy is another important complication in kidney transplant recipients, and JC virus–associated PML, though rare, is potentially fatal and requires a high index of clinical suspicion.

How Should You Store Mycophenolate Mofetil Teva?

Proper storage of Mycophenolate Mofetil Teva is important to maintain the stability, efficacy, and safety of the medication throughout its shelf life. The film-coated tablets should be stored at a temperature not exceeding 30°C (86°F). There is no requirement for refrigeration, making this medication convenient for home storage in most climates. However, the tablets should be kept in their original packaging (blister pack or bottle) to protect them from moisture, as mycophenolate mofetil can be sensitive to humidity.

Keep the medication out of the sight and reach of children at all times. This is particularly important for mycophenolate mofetil given its teratogenic potential and the risk of serious adverse effects. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of that month. If you have any unused or expired medication, do not dispose of it via household waste or wastewater. Return it to your pharmacy for safe disposal in accordance with local regulations. This helps to protect the environment.

If you notice any visible change in the appearance of the tablets, such as discolouration, crumbling, or an unusual odour, do not take them and consult your pharmacist. Tablets that have been stored outside their original packaging or in excessive heat or humidity may have reduced potency and should not be used. When travelling, keep the medication in your hand luggage to avoid exposure to extreme temperatures in the cargo hold of aircraft, and carry it in its original packaging with the prescription label clearly visible.

What Does Mycophenolate Mofetil Teva Contain?

Mycophenolate Mofetil Teva 500 mg film-coated tablets contain the following ingredients:

Active substance: Each film-coated tablet contains 500 mg of mycophenolate mofetil. Mycophenolate mofetil (chemical name: 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate) is a white to off-white crystalline powder. It has a molecular weight of 433.50 g/mol and is slightly soluble in water.

Excipients (inactive ingredients):

• Tablet core: Microcrystalline cellulose, povidone K-30, croscarmellose sodium, and magnesium stearate. These excipients serve as fillers, binders, disintegrants, and lubricants to ensure consistent tablet manufacture and appropriate drug release characteristics.
• Film coating: Hypromellose (hydroxypropyl methylcellulose), titanium dioxide (E171), and macrogol/polyethylene glycol. The film coating protects the tablet core, improves swallowability, and provides the characteristic appearance of the tablet. Some formulations may also contain iron oxide pigments for colouring.

Mycophenolate Mofetil Teva 500 mg tablets are typically lavender-coloured, capsule-shaped, film-coated tablets. They may be scored on one side for identification purposes, though they should not be divided for dosing as the score line is not intended for splitting. The tablets are packaged in blister packs or HDPE bottles with child-resistant closures. Always check the specific appearance and packaging details on the patient information leaflet included with your medication, as these may vary between batches or regional formulations.